153 related articles for article (PubMed ID: 28336343)
1. Viral delivered gene therapy to treat catecholaminergic polymorphic ventricular tachycardia (CPVT2) in mouse models.
Kurtzwald-Josefson E; Yadin D; Harun-Khun S; Waldman M; Aravot D; Shainberg A; Eldar M; Hochhauser E; Arad M
Heart Rhythm; 2017 Jul; 14(7):1053-1060. PubMed ID: 28336343
[TBL] [Abstract][Full Text] [Related]
2. The role of mutant protein level in autosomal recessive catecholamine dependent polymorphic ventricular tachycardia (CPVT2).
Katz G; Shainberg A; Hochhauser E; Kurtzwald-Josefson E; Issac A; El-Ani D; Aravot D; Afek A; Seidman JG; Seidman CE; Eldar M; Arad M
Biochem Pharmacol; 2013 Dec; 86(11):1576-83. PubMed ID: 24070655
[TBL] [Abstract][Full Text] [Related]
3. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
4. Single delivery of an adeno-associated viral construct to transfer the CASQ2 gene to knock-in mice affected by catecholaminergic polymorphic ventricular tachycardia is able to cure the disease from birth to advanced age.
Denegri M; Bongianino R; Lodola F; Boncompagni S; De Giusti VC; Avelino-Cruz JE; Liu N; Persampieri S; Curcio A; Esposito F; Pietrangelo L; Marty I; Villani L; Moyaho A; Baiardi P; Auricchio A; Protasi F; Napolitano C; Priori SG
Circulation; 2014 Jun; 129(25):2673-81. PubMed ID: 24888331
[TBL] [Abstract][Full Text] [Related]
5. Alpha blockade potentiates CPVT therapy in calsequestrin-mutant mice.
Kurtzwald-Josefson E; Hochhauser E; Bogachenko K; Harun-Khun S; Katz G; Aravot D; Seidman JG; Seidman CE; Eldar M; Shainberg A; Arad M
Heart Rhythm; 2014 Aug; 11(8):1471-9. PubMed ID: 24768611
[TBL] [Abstract][Full Text] [Related]
6. Adeno-associated virus-mediated CASQ2 delivery rescues phenotypic alterations in a patient-specific model of recessive catecholaminergic polymorphic ventricular tachycardia.
Lodola F; Morone D; Denegri M; Bongianino R; Nakahama H; Rutigliano L; Gosetti R; Rizzo G; Vollero A; Buonocore M; Napolitano C; Condorelli G; Priori SG; Di Pasquale E
Cell Death Dis; 2016 Oct; 7(10):e2393. PubMed ID: 27711080
[TBL] [Abstract][Full Text] [Related]
7. Gene Transfer of Engineered Calmodulin Alleviates Ventricular Arrhythmias in a Calsequestrin-Associated Mouse Model of Catecholaminergic Polymorphic Ventricular Tachycardia.
Liu B; Walton SD; Ho HT; Belevych AE; Tikunova SB; Bonilla I; Shettigar V; Knollmann BC; Priori SG; Volpe P; Radwański PB; Davis JP; Györke S
J Am Heart Assoc; 2018 May; 7(10):. PubMed ID: 29720499
[TBL] [Abstract][Full Text] [Related]
8. Impaired Dynamic Sarcoplasmic Reticulum Ca Buffering in Autosomal Dominant CPVT2.
Wleklinski MJ; Kryshtal DO; Kim K; Parikh SS; Blackwell DJ; Marty I; Iyer VR; Knollmann BC
Circ Res; 2022 Sep; 131(8):673-686. PubMed ID: 36102198
[TBL] [Abstract][Full Text] [Related]
9. Molecular adaptation to calsequestrin 2 (CASQ2) point mutations leading to catecholaminergic polymorphic ventricular tachycardia (CPVT): comparative analysis of R33Q and D307H mutants.
Valle G; Arad M; Volpe P
J Muscle Res Cell Motil; 2020 Sep; 41(2-3):251-258. PubMed ID: 32902830
[TBL] [Abstract][Full Text] [Related]
10. Abnormal calcium signaling and sudden cardiac death associated with mutation of calsequestrin.
Viatchenko-Karpinski S; Terentyev D; Györke I; Terentyeva R; Volpe P; Priori SG; Napolitano C; Nori A; Williams SC; Györke S
Circ Res; 2004 Mar; 94(4):471-7. PubMed ID: 14715535
[TBL] [Abstract][Full Text] [Related]
11. Viral gene transfer rescues arrhythmogenic phenotype and ultrastructural abnormalities in adult calsequestrin-null mice with inherited arrhythmias.
Denegri M; Avelino-Cruz JE; Boncompagni S; De Simone SA; Auricchio A; Villani L; Volpe P; Protasi F; Napolitano C; Priori SG
Circ Res; 2012 Mar; 110(5):663-8. PubMed ID: 22298808
[TBL] [Abstract][Full Text] [Related]
12. Functional abnormalities in iPSC-derived cardiomyocytes generated from CPVT1 and CPVT2 patients carrying ryanodine or calsequestrin mutations.
Novak A; Barad L; Lorber A; Gherghiceanu M; Reiter I; Eisen B; Eldor L; Itskovitz-Eldor J; Eldar M; Arad M; Binah O
J Cell Mol Med; 2015 Aug; 19(8):2006-18. PubMed ID: 26153920
[TBL] [Abstract][Full Text] [Related]
13. Calsequestrin mutation and catecholaminergic polymorphic ventricular tachycardia: a simulation study of cellular mechanism.
Faber GM; Rudy Y
Cardiovasc Res; 2007 Jul; 75(1):79-88. PubMed ID: 17531962
[TBL] [Abstract][Full Text] [Related]
14. Catecholaminergic polymorphic ventricular tachycardia (and seizure) caused by a novel homozygous likely pathogenic variant in CASQ2 gene.
Askarinejad A; Esmaeili S; Dalili M; Biglari A; Kohansal E; Maleki M; Kalayinia S
Gene; 2024 Feb; 895():148012. PubMed ID: 37995796
[TBL] [Abstract][Full Text] [Related]
15. A mutation in calsequestrin, CASQ2D307H, impairs Sarcoplasmic Reticulum Ca2+ handling and causes complex ventricular arrhythmias in mice.
Dirksen WP; Lacombe VA; Chi M; Kalyanasundaram A; Viatchenko-Karpinski S; Terentyev D; Zhou Z; Vedamoorthyrao S; Li N; Chiamvimonvat N; Carnes CA; Franzini-Armstrong C; Györke S; Periasamy M
Cardiovasc Res; 2007 Jul; 75(1):69-78. PubMed ID: 17449018
[TBL] [Abstract][Full Text] [Related]
16. Optimizing catecholaminergic polymorphic ventricular tachycardia therapy in calsequestrin-mutant mice.
Katz G; Khoury A; Kurtzwald E; Hochhauser E; Porat E; Shainberg A; Seidman JG; Seidman CE; Lorber A; Eldar M; Arad M
Heart Rhythm; 2010 Nov; 7(11):1676-82. PubMed ID: 20620233
[TBL] [Abstract][Full Text] [Related]
17. Exercise training improves cardiac function and attenuates arrhythmia in CPVT mice.
Kurtzwald-Josefson E; Hochhauser E; Katz G; Porat E; Seidman JG; Seidman CE; Chepurko Y; Shainberg A; Eldar M; Arad M
J Appl Physiol (1985); 2012 Dec; 113(11):1677-83. PubMed ID: 23042908
[TBL] [Abstract][Full Text] [Related]
18. Patient-Specific Drug Screening Using a Human Induced Pluripotent Stem Cell Model of Catecholaminergic Polymorphic Ventricular Tachycardia Type 2.
Maizels L; Huber I; Arbel G; Tijsen AJ; Gepstein A; Khoury A; Gepstein L
Circ Arrhythm Electrophysiol; 2017 Jun; 10(6):. PubMed ID: 28630169
[TBL] [Abstract][Full Text] [Related]
19. Functional consequences of stably expressing a mutant calsequestrin (CASQ2D307H) in the CASQ2 null background.
Kalyanasundaram A; Viatchenko-Karpinski S; Belevych AE; Lacombe VA; Hwang HS; Knollmann BC; Gyorke S; Periasamy M
Am J Physiol Heart Circ Physiol; 2012 Jan; 302(1):H253-61. PubMed ID: 21984545
[TBL] [Abstract][Full Text] [Related]
20. Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
Faggioni M; Kryshtal DO; Knollmann BC
Pediatr Cardiol; 2012 Aug; 33(6):959-67. PubMed ID: 22421959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
